Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
Bolun Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Qiu(Shandong Academy of Agricultural Sciences), Wei Guo(Chinese Academy of Medical Sciences & Peking Union Medical College), Ning Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Li J(Zhejiang Medicine (China)), Fan Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Zhao(Linyi City Chinese Medicine Hospital), Fang Lv(Liaoning Normal University), Shuhang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Kang Shao(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 8
Related Papers
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
|Nature Genetics|2009|944
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Mouse Embryonic Head as a Site for Hematopoietic Stem Cell Development
|Cell stem cell|2012|192
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128